- Home
- AMS vs INTS Comparison
AMS vs INTS Comparison
Compare AMS & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMS
- INTS
- Stock Information
- Founded
- AMS 1980
- INTS 2012
- Country
- AMS United States
- INTS United States
- Employees
- AMS N/A
- INTS N/A
- Industry
- AMS Medical Specialities
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- AMS Health Care
- INTS Health Care
- Exchange
- AMS Nasdaq
- INTS Nasdaq
- Market Cap
- AMS 14.7M
- INTS 12.2M
- IPO Year
- AMS N/A
- INTS 2023
- Fundamental
- Price
- AMS $2.10
- INTS $0.54
- Analyst Decision
- AMS
- INTS Strong Buy
- Analyst Count
- AMS 0
- INTS 4
- Target Price
- AMS N/A
- INTS $4.50
- AVG Volume (30 Days)
- AMS 26.1K
- INTS 86.0M
- Earning Date
- AMS 11-11-2025
- INTS 11-07-2025
- Dividend Yield
- AMS N/A
- INTS N/A
- EPS Growth
- AMS N/A
- INTS N/A
- EPS
- AMS N/A
- INTS N/A
- Revenue
- AMS $29,251,000.00
- INTS N/A
- Revenue This Year
- AMS $5.06
- INTS N/A
- Revenue Next Year
- AMS N/A
- INTS N/A
- P/E Ratio
- AMS N/A
- INTS N/A
- Revenue Growth
- AMS 26.61
- INTS N/A
- 52 Week Low
- AMS $2.01
- INTS $0.19
- 52 Week High
- AMS $3.59
- INTS $3.40
- Technical
- Relative Strength Index (RSI)
- AMS 36.94
- INTS 54.50
- Support Level
- AMS $2.02
- INTS $0.23
- Resistance Level
- AMS $2.38
- INTS $1.74
- Average True Range (ATR)
- AMS 0.09
- INTS 0.15
- MACD
- AMS -0.02
- INTS 0.04
- Stochastic Oscillator
- AMS 22.22
- INTS 20.51
About AMS American Shared Hospital Services
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.